ログイン
ランキング
お知らせ
ログイン
文献詳細
特集 NPSLE
文献概要
進行性多巣性白質脳症（PML）の概説と，全身性エリテマトーデス（SLE）におけるPMLの特徴を論じた。PML診療は病態修飾療法（DMT）関連PMLに対応する時代であり，特に多発性硬化症のDMT関連PMLが注目されている。SLEにおけるPMLの発症は非常に稀ではあるが，SLEでも従来の免疫抑制剤などによる日和見感染としての薬剤関連PMLのみでなく，DMT関連PMLの可能性も考慮し診療する必要がある。
参考文献
1)Tan CS, Koralnik IJ: Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 9: 425-437, 2010
2)Brew BJ, Davies NW, Cinque P, Clifford DB, Nath A: Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol 6: 667-679, 2010
3)Taguchi F, Kajioka J, Miyamura T: Prevalence rate and age of acquisition of antibodies against JC virus and BK virus in human sera. Microbiol Immunol 26: 1057-1064, 1982
4)Ferenczy MW, Marshall LJ, Nelson CD, Atwood WJ, Nath A, et al: Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 25: 471-506, 2012
5)厚生労働科学研究費補助金 難治性疾患等克服研究事業（難治性疾患克服研究事業）プリオン病及び遅発性ウイルス感染症に関する調査研究班（編）: 進行性多巣性白質脳症（Progressive Multifocal Leukoencephalopathy: PML）診療ガイドライン2013. http://prion.umin.jp/file/PML2013.pdf（最終閲覧日: 2019年2月15日）
6)Åström KE, Mancall EL, Richardson EP Jr: Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 81: 93-111, 1958
7)Berger JR, Kaszovitz B, Post MJ, Dickinson G: Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases. Ann Intern Med 107: 78-87, 1987
8)Amend KL, Turnbull B, Foskett N, Napalkov P, Kurth T, et al: Incidence of progressive multifocal leukoencephalopathy in patients without HIV. Neurology 75: 1326-1332, 2010
9)Yukitake M: Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: a comprehensive review. Clin Exp Neuroimmunol 9(Suppl. 1): 37-47, 2018
10)Vargas DL, Tyor WR: Update on disease-modifying therapies for multiple sclerosis. J Investig Med 65: 883-891, 2017
11)Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, et al: Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366: 1870-1880, 2012
12)Piccinni C, Sacripanti C, Poluzzi E, Motola D, Magro L, et al: Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents. Eur J Clin Pharmacol 66: 199-206, 2010
13)Dong-Si T, Richman S, Wattjes MP, Wenten M, Gheuens S, et al: Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. Ann Clin Transl Neurol 1: 755-764, 2014
14)厚生労働科学研究費補助金 難治性疾患等政策研究事業（難治性疾患政策研究事業）プリオン病及び遅発性ウイルス感染症に関する調査研究班（編）: 進行性多巣性白質脳症（Progressive Multifocal Leukoencephalopathy: PML）診療ガイドライン2017. http://prion.umin.jp/guideline/guideline_PML_2017.pdf（最終閲覧日: 2019年2月15日）
15)Pavlovic D, Patera AC, Nyberg F, Gerber M, Liu M: Progressive multifocal leukoencephalopathy: current treatment options and future perspectives. Ther Adv Neurol Disord 8: 255-273, 2015
16)Tan IL, McArthur JC, Clifford DB, Major EO, Nath A: Immune reconstitution inflammatory syndrome in Natalizumab-associated PML. Neurology 77: 1061-1067, 2011
17)Tan K, Roda R, Ostrow L, McArthur J, Nath A: PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 72: 1458-1464, 2009
18)Shah R, Bag AK, Chapman PR, Curé JK: Imaging manifestations of progressive multifocal leukoencephalopathy. Clin Radiol 65: 431-439, 2010
19)Yousry TA, Pelletier D, Cadavid D, Gass A, Richert ND, et al: Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 72: 779-787, 2012
20)Wattjes MP, Barkhof F: Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. Curr Opin Neurol 27: 260-270, 2014
21)Hodel J, Darchis C, Outteryck O, Verclytte S, Deramecourt V, et al: Punctate pattern: a promising imaging marker for the diagnosis of natalizumab-associated PML. Neurology 86: 1516-1523, 2016
22)Gieselbach RJ, Muller-Hansma AH, Wijburg MT, de Bruin-Weller MS, van Oosten BW, et al: Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases. J Neurol 264: 1155-1164, 2017
23)Hodel J, Outteryck O, Dubron C, Dutouquet B, Benadjaoud MA, et al: Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab: diagnostic precision with MR imaging. Radiology 278: 863-872, 2016
24)Yousry TA, Pelletier D, Cadavid D, Gass A, Richert ND, et al: Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 72: 779-787, 2012
25)Cinque P, Koralnik IJ, Gerevini S, Miro JM, Price RW: Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis 9: 625-636, 2009
26)Ryschkewitsch CF, Jensen PN, Major EO: Multiplex qPCR assay for ultrasensitive detection of JCV DNA with simultaneous identification of genotypes that discriminates non-virulent from virulent variants. J Clin Virol 57: 243-248, 2013
27)Nakamichi K, Kishida S, Tanaka K, Suganuma A, Sano Y, et al: Sequential changes in the non-coding control region sequences of JC polyomaviruses from the cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. Arch Virol 158: 639-650, 2013
28)Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, et al: PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 80: 1430-1438, 2013
29)Nishiyama S, Misu T, Shishido-Hara Y, Nakamichi K, Saijo M, et al: Fingolimod-associated PML with mild IRIS in MS: a clinicopathologic study. Neurol Neuroimmunol Neuroinflamm 5: e415, 2018［doi: https://doi.org/10.1212/NXI.0000000000000415］
30)Albrecht H, Hoffmann C, Degen O, Stoehr A, Plettenberg A, et al: Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. AIDS 12: 1149-1154, 1998
31)Gasnault J, Costagliola D, Hendel-Chavez H, Dulioust A, Pakianather S, et al: Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy. PLOS ONE 6: e20967, 2011［doi: 10.1371/journal.pone.0020967］
32)Crowder CD, Gyure KA, Drachenberg CB, Werner J, Morales RE, et al: Successful outcome of progressive multifocal leukoencephalopathy in a renal transplant patient. Am J Transplant 5: 1151-1158, 2005
33)Vulliemoz S, Lurati-Ruiz F, Borruat FX, Delavelle J, Koralnik IJ, et al: Favourable outcome of progressive multifocal leucoencephalopathy in two patients with dermatomyositis. J Neurol Neurosurg Psychiatry 77: 1079-1082, 2006
34)Wenning W, Haghikia A, Laubenberger J, Clifford DB, Behrens PF, et al: Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 361: 1075-1080, 2009
35)Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, et al: Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9: 438-446, 2010
36)Clifford DB, Nath A, Cinque P, Brew BJ, Zivadinov R, et al: A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J Neurovirol 19: 351-358, 2013
37)Antinori A, Cingolani A, Lorenzini P, Giancola ML, Uccella I, et al: Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol 9(Suppl 1): 47-53, 2003
38)Tan CS, Chen Y, Viscidi RP, Kinkel RP, Stein MC, et al: Discrepant findings in immune responses to JC virus in patients receiving natalizumab. Lancet Neurol 9: 565-566, 2010
39)雪竹基弘: Neuropsychiatric SLE（NPSLE）. 辻 省次, 吉良潤一（編）, 免疫性神経疾患—病態と治療のすべて. 中山書店, 東京, 2016, pp.402-408
40)Hanly JG: Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol 10: 338-347, 2014
41)Muscal E, Brey RL: Neurologic manifestations of systemic lupus erythematosus in children and adults. Neurol Clin 28: 61-73, 2010
42)西村勝治, 佐藤恵理: 全身性エリテマトーデス（SLE）における精神障害. 総病精医23: 42-51, 2011
43)Hanly JG, Urowitz MB, Sanchez-Guerrero J, Bae SC, Gordon C, et al: Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum 56: 265-273, 2007
44)Yang CD, Wang XD, Ye S, Gu YY, Bao CD, et al: Clinical features, prognostic and risk factors of central nervous system infections in patients with systemic lupus erythematosus. Clin Rheumatol 26: 895-901, 2007
45)Vargas PJ, King G, Navarra SV: Central nervous system infections in Filipino patients with systemic lupus erythematosus. Int J Rheum Dis 12: 234-238, 2009
46)Fang H, Lan L, Qu Y, Zhang Q, Lv J: Differences between central nervous system infection and neuropsychiatric systemic lupus erythematosus in patients with systemic lupus erythematosus. J Int Med Res 46: 485-491, 2018
47)Molloy ES, Calabrese LH: Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 60: 3761-3765, 2009
48)Henegar CE, Eudy AM, Kharat V, Hill DD, Bennett D, et al: Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review. Lupus 25: 617-626, 2016
49)Engsig FN, Hansen AB, Omland LH, Kronborg G, Gerstoft J, et al: Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis 199: 77-83, 2009
50)Biogen MedInfo: Tysabri®(natalizumab) Prescribing Information. https://www.tysabri.com/content/dam/commercial/multiple-sclerosis/tysabri/pat/en_us/pdfs/tysabri_prescribing_information.pdf（最終閲覧日: 2019年2月19日）
51)Berger JR: Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord 12: 59-63, 2017
52)Fredericks CA, Kvam KA, Bear J, Crabtree GS, Josephson SA: A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab. Lupus 23: 711-713, 2014
53)ACR ad hoc Committee on Neuropsychiatric Lupus Nomenclature: The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42: 599-608, 1999
54)Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A: The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 57: 496-500, 2001
55)Brey RL, Holliday SL, Saklad AR, Navarrete MG, Hermosillo-Romo D, et al: Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 58: 1214-1220, 2002
56)Unterman A, Nolte JE, Boaz M, Abady M, Shoenfeld Y, et al: Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum 41: 1-11, 2011
57)Ishii J, Shishido-Hara Y, Kawamoto M, Fujiwara S, Imai Y, et al: A punctate magnetic resonance imaging pattern in a patient with systemic lupus erythematosus is an early sign of progressive multifocal leukoencephalopathy: a clinicopathological study. Intern Med 57: 2727-2734, 2018
58)柳下 章: 全身性エリテマトーデス（systemic lupus erythematosus: SLE）. 柳下 章（編）, 神経内科疾患の画像診断 第2版. 秀潤社, 東京, 2019, p704
59)Iacobaeus E, Hopia L, Khademi M, Lundén M, Hammarin AL, et al: Analysis of JC virus DNA in NPSLE patients treated with different immunomodulatory agents. Lupus 22: 307-311, 2013
60)Molloy ES, Calabrese LH: Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun Rev 8: 144-146, 2008
61)Berger JR, Pall L, Lanska D, Whiteman M: Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol 4: 59-68, 1998
62)加納裕也, 井上裕康, 櫻井圭太, 吉田眞理, 三浦義治, 他: 髄液JCウイルス（JCV）-DNA PCR陰性で脳生検で診断した, 特発性CD4陽性リンパ球減少症が関連した進行性多巣性白質脳症の1例. 臨床神経58: 750-755, 2018
63)Brandão M, Damásio J, Marinho A, da Silva AM, Vasconcelos J, et al: Systemic lupus erythematosus, progressive multifocal leukoencephalopathy, and T-CD4+ lymphopenia. Clin Rev Allergy Immunol 43: 302-307, 2012
64)Pavlovic AM, Bonaci-Nikolic B, Kozic D, Ostojic J, Abinun M, et al: Progressive multifocal leukoencephalopathy associated with mycophenolate mofetil treatment in a woman with lupus and CD4+ T-lymphocyte deficiency. Lupus 21: 100-102, 2012
65)Ishikawa Y, Kasuya T, Ishikawa J, Fujiwara M, Kita Y: A case of developing progressive multifocal leukoencephalopathy while using rituximab and mycophenolate mofetil in refractory systemic lupus erythematosus. Ther Clin Risk Manag 26: 1149-1153, 2018
66)Berntsson SG, Katsarogiannis E, Lourenço F, Moraes-Fontes MF: Progressive multifocal leukoencephalopathy and systemic lupus erythematosus: focus on etiology. Case Rep Neurol 8: 59-65, 2016
掲載誌情報
